The test MRSA and MSSA directly from blood culture samples in about one hour, compared to between 48 and 72 hours with other methods, the company said.
The acquisition allows Sysmex to enter the cytogenetics market and strengthens its technology base in molecular genetics, while expanding its life science business.
The researchers will use single-cell genomics and other approaches to generate information that could ultimately be used to diagnose, monitor, and treat disease.
The companion test will let doctors identify the best treatment for CLL patients with 17p deletions, a subset that has historically lacked therapeutic options.
The new system emphasizes the importance of tumor biology as an important prognostic indicator for women who undergo neoadjuvant therapy, the researchers said.
